Neurocrine Biosciences, Inc. (0K6R.L) LSE

Currency In USD

AD

Valuation

Market Cap14.12B
Enterprise Value14.29B
P/E Ratio21.64
PEG Ratio0.21
Price/Sales Ratio4.55
Price/Book Ratio4.17
Enterprise/Revenue4.57
Enterprise/EBITDA16.79

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin0.21
Operating Margin0.23
AD

Management Effectiveness

Return On Assets0.13
Return On Equity0.21

Income Statement

Revenue2.86B
Revenue/Share33.4
Gross Profit2.81B
EBITDA666.6M
Net Income478.6M
Diluted EPS4.67

Balance Sheet

Total Cash389.8M
Total Cash/Share3.86
Total Debt401.8M
Total Debt/Equity0.11
Current Ratio1.87
Book Value Per Share36.57

Price History

52-Week Change13.3
52-Week High155.98
52-Week Low89.66
Moving Average 50 Days135.58
Moving Average 200 Days114.15

Statistics

Average Volume1,189
Shares Outstanding100.25M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split FactorN/A
Last Split DateN/A
AD